Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Gene Therapy (SPVN20) in Subjects With Rod-Cone Dystrophy

ClinicalTrials.gov ID

NCT07807111

Lead Sponsor

SparingVisionINDUSTRY

Overall Status

Recruiting

Study Type

Interventional

Phase

Phase 1Phase 2

Enrollment

27Estimated

Last Update Posted

Sep 8, 2026Actual

Start Date

Oct 8, 2025Actual

Primary Completion Date

Mar 2032Estimated

Completion Date

Mar 2032Estimated

Official Title

A Phase I/IIa Clinical Trial to Assess the Safety, Tolerability, and Efficacy of a Single Intravitreal Injection of SPVN20 Gene Therapy in Participants With Advanced Rod-Cone Dystrophy

Brief Summary

This open-label, multi-center study is to evaluate the safety, tolerability, and efficacy of escalating doses of a gene therapy called SPVN20 administered via a single intravitreal injection in participants with advanced Rod-Cone Dystrophy.

Detailed Description

This is an open-label, non-randomized, multi-center, dose-escalation and dose-expansion, first-in-human, Phase I/IIa study. Participants will be followed for a total of five years after receiving a single unilateral intravitreal injection of SPVN20 in their study eye, and will be monitored by an independent Data Safety Monitoring Committee. Eligible patients will be assigned by sequential enrollment to one of the following three cohorts:

Cohort 1: low dose of SPVN20 will be evaluated in a total of 9 participants. Cohort 2: medium dose of SPVN20 will be evaluated in a total of 9 participants. Cohort 3: high dose of SPVN20 will be evaluated in a total of 9 participants.

• Retinitis Pigmentosa (RP)
• Rod Cone Dystrophy

• SPVN20 (high dose)
• SPVN20 (medium dose)
• SPVN20 (low dose)

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

1. Age ≥ 18 years old at enrollment.
2. Participant with a genetically confirmed clinical diagnosis of advanced RCD in both eyes due to non-syndromic RCD.
3. Participants enrolled in the Dose-Escalation cohorts must have a BCVA meeting the study eye criteria.
4. Documented preservation of foveal cone cell bodies in the study eye (as shown on SD-OCT imaging).
5. Participant with a history of formed vision.
6. Participant willing and able to provide informed consent.

Exclusion Criteria:

1. Participant participating in another clinical trial and receiving an investigational medicinal product (IMP) within either 5 half-lives of that IMP, or 90 days prior to the injection of SPVN20.
2. Participant with cortical visual impairment.
3. Participant with systemic disease or other pathology not related to their diagnosis of RCD, and whose symptoms or associated treatments may affect vision.
4. Participant with known allergies to corticosteroids, or who will be unable to tolerate the corticosteroid regimen.
5. Participant who has received immunosuppressive therapies or any other therapy known to impact the immune system during the last month prior to SPVN20 administration.
6. Active ocular inflammation or recurrent history of idiopathic or autoimmune-associated uveitis.
7. Participant known to be allergic to any of the delivery vehicle constituents or to any other drugs planned to be used during the clinical study.
8. Active alcohol or substance abuse.
9. Participant positive for human immunodeficiency virus (HIV) or any other systemic immunocompromising disease.
10. Participant with active Hepatitis B or Hepatitis C.
11. Female participant currently pregnant or breastfeeding or intending to become pregnant.
12. Participant with clinically active ocular infection of herpetic diseases.
13. Participant with active coronavirus disease (COVID-19) infection.
14. Participant who received any vaccination/immunization within 28 days prior to screening and/or during screening.
15. Participant who previously received any gene therapy product, stem cell therapy, cell-based therapy for ocular or non-ocular disease.
16. Participant with a retinal implant at enrollment.
17. Participant with pre-existing eye conditions that would interfere with the interpretation of study endpoints, or increase the risk of surgical complications.
18. Participant with significant media opacity impacting evaluation of the retina or vitreous.
19. Participant who had intraocular surgery within 90 days of study treatment administration.
20. Participant with history of corticosteroid-induced raised IOP of >25 mmHg following corticosteroid exposure, despite topical IOP-lowering pharmacologic therapy.
21. Participant with history of unresolved rhegmatogenous retinal detachment in the fovea.
22. Participant with history of unresolved ocular hypotony.
23. Participant unwilling or unable (based on the Investigator's judgment) to comply with the study protocol.
24. Participant with any condition that would not allow them to complete follow-up examinations during the study and, in the opinion of the Investigator, would make them unsuitable for the study.
25. Participant currently taking restricted classes of medications listed in protocol
26. Participant with ongoing cardiac or neurological disorders not managed by a restricted medication can be excluded based on the Investigator's judgement.
27. Women of childbearing potential (WOCBP) and men and/or their partner(s) of childbearing potential who do not agree to use a highly effective contraceptive method.

Primary Purpose

Treatment

Allocation

Non-Randomized

Interventional Model

Sequential Assignment

Masking

None (Open Label)

Lead Sponsor

SparingVisionINDUSTRY

ddagostinoz@15-20.fr00 33 1 40 02 15 20

Emma.duignan@rveeh.ie00 353 1 664 4600

• Promising ROd-cone DYstrophy Gene therapY

  NCT05748873

  Active, not recruitingInterventionalPhase 1Phase 2Updated May 15, 2026
• A Dose Ranging Study to Evaluate the Safety and Potential Efficacy of rhNGF in Patients With Retinitis Pigmentosa (RP)

  NCT02110225

  CompletedInterventionalPhase 1Phase 2Updated Apr 18, 2024
• AGN-151597 (Formerly RST-001) Phase I/II Trial for Advanced Retinitis Pigmentosa

  NCT02556736

  CompletedInterventionalPhase 1Phase 2Updated Jan 12, 2026
• Dose-Escalation Study to Evaluate the Safety and Tolerability of Intravitreal vMCO-I in Patients With Advanced Retinitis Pigmentosa

  NCT04919473

  CompletedInterventionalPhase 1Phase 2Updated Jun 9, 2021
• Prospective, Randomized, Sham-controlled, Dose-finding I/II Trial of Safety and Efficacy of Modified Optogenetic Gene Therapy (ZM-02 Injection)

  NCT07282457

  Not yet recruitingInterventionalPhase 1Phase 2Updated Apr 13, 2026
• Dose-escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa

  NCT03326336

  Active, not recruitingInterventionalPhase 1Phase 2Updated Mar 2, 2026